{
    "clinical_study": {
        "@rank": "68737", 
        "acronym": "PPB", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Biopsy", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study's objective is to obtain preliminary data to test the hypotheses that\n      percutaneous liver biopsy in brain death donors is safe and provides reliable histological\n      information. Furthermore, that information when disseminated fully and widely many hours\n      before organ recovery would not only decrease economic costs of wasteful recovery of livers\n      that are not ultimately transplanted but also increase transplantation and decrease cold\n      ischemia times of recovered livers."
        }, 
        "brief_title": "Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors", 
        "condition": [
            "Neurological Death", 
            "Organ Donation", 
            "Liver Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Death", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Neurological death donors in whom brain death determination is imminent\n\n          -  First person or next of kin consent for research becomes available\n\n          -  High risk donor, as defined by the following criteria i) Known liver disease ii)\n             Hepatitis BsAg, BcAb, B DNA, Hepatitis C Ab or Hepatitis C RNA positivity iii) Age >=\n             50 iv) Any of the following risk factors for fatty liver disease a) BMI >= 30 b)\n             History of Type 2 Diabetes Mellitus c) Ultrasound, Computerized Tomography or other\n             imaging modalities             suggesting steatosis v) Any of the following risk\n             factors for chronic liver disease\n\n               1. Greater than 2 drinks of alcohol daily currently or in their history\n\n               2. Current IV drug use\n\n               3. Ultrasound, Computerized Tomography or other imaging modalities suggesting\n                  cirrhosis\n\n        Exclusion Criteria:\n\n          -  Donation after cardiac death donors\n\n          -  Live organ donors\n\n          -  No first person consent and next of kin decline research consent\n\n          -  Donors in whom it has been established the liver will not be shared\n\n          -  Donors in whom percutaneous liver biopsy has been performed within the past month for\n             any indication and the biopsy results are available and considered reliable.\n\n          -  Donor with a contraindication to liver biopsy, including INR > 2, PTT > 75, Platelets\n             < 70,000, history of coagulopathy, current or recent use (within 7 days) of\n             antiplatelet agent such as aspirin or Plavix, and hemodynamic instability defined as\n             a MAP less than 65mmHg.\n\n          -  Inability to position donor appropriately for performance of PPB\n\n          -  Unavailability of pathology staff to analyze specimen in a timely manner"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810640", 
            "org_study_id": "2012002002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Biopsy", 
                "description": "Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies.  Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation.  Slides will then be digitalized and shared on Donor.net.", 
                "intervention_name": "Percutaneous Liver Biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "Bedside Liver Biopsy"
            }, 
            {
                "arm_group_label": [
                    "Control", 
                    "Biopsy"
                ], 
                "description": "During time of liver procurement, a wedge from the right lobe of the liver and two needle cores using a Tru-cut needle, will be obtained and placed in 10% formalin and embedded in paraffin blocks, cut to 5 microns and stained with hematoxylin and eosin.", 
                "intervention_name": "Wedge and Core Liver Biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "Intraoperative liver biopsy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Liver Extracts"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver biopsy", 
            "organ donation", 
            "donor management"
        ], 
        "lastchanged_date": "March 11, 2013", 
        "location": [
            {
                "contact": {
                    "email": "koneruba@umdnj.edu", 
                    "last_name": "Babuaro Koneru, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New Providence", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07974"
                    }, 
                    "name": "New Jersey Organ and Sharing Network"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07101"
                    }, 
                    "name": "University Hospital"
                }, 
                "investigator": {
                    "last_name": "Baburao Koneru, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study", 
        "overall_contact": {
            "email": "koneruba@umdnj.edu", 
            "last_name": "Babuaro Koneru, MD", 
            "phone": "9739729599"
        }, 
        "overall_contact_backup": {
            "email": "oliverjo@umdnj.edu", 
            "last_name": "Joseph Oliver, MD", 
            "phone": "9739726516"
        }, 
        "overall_official": {
            "affiliation": "UMDNJ - New Jersey Medical School", 
            "last_name": "Babuaro Koneru, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety of bedside liver biopsy will be measured as the presence or absence of a composite outcome of: change in hemoglobin (gm/dL) from baseline of greater than 2, occurence of pneumothorax on right side observed on chest X-ray immediately after biopsy, and/or donor instability leading to expedited organ recover, and/or loss of donor organs attributed to the biopsy", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 hours"
            }, 
            {
                "description": "Agreement of the findings of the bedside biopsy with reference to an intraoperative biopsy in histological characteristics of steatosis, inflammation, and fibrosis", 
                "measure": "Reliability", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }, 
            {
                "description": "The proportion of donors in the biopsy group in whom PPB information becomes available prior to commencement of organ recovery", 
                "measure": "Feasibility", 
                "safety_issue": "No", 
                "time_frame": "24hrs"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810640"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Medicine and Dentistry New Jersey", 
            "investigator_full_name": "Baburao Koneru", 
            "investigator_title": "Professor of Surgery, Division Chief Liver Transplantation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Time between performance of biopsy and availability of results to the sharing network", 
            "measure": "Feasibility", 
            "safety_issue": "No", 
            "time_frame": "24hrs"
        }, 
        "source": "Rutgers, The State University of New Jersey", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Medicine and Dentistry of New Jersey", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}